↓ Skip to main content

Cochrane Database of Systematic Reviews

Milnacipran for neuropathic pain in adults

Overview of attention for article published in Cochrane database of systematic reviews, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
37 Dimensions

Readers on

mendeley
165 Mendeley
Title
Milnacipran for neuropathic pain in adults
Published in
Cochrane database of systematic reviews, July 2015
DOI 10.1002/14651858.cd011789
Pubmed ID
Authors

Sheena Derry, Tudor Phillips, R Andrew Moore, Philip J Wiffen

Abstract

Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is sometimes used to treat chronic neuropathic pain and fibromyalgia. This is an update of an earlier review of milnacipran for neuropathic pain and fibromyalgia in adults originally published in The Cochrane Library Issue 3, 2012. We split that review so that this one looked only at neuropathic pain, and a separate review looks at fibromyalgia. To assess the analgesic efficacy and associated adverse events of milnacipran for chronic neuropathic pain in adults. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE to 23 February 2015, together with reference lists of retrieved papers and reviews. We included randomised, double-blind studies of eight weeks' duration or longer, comparing milnacipran with placebo or another active treatment in chronic neuropathic pain. Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any analysis. We included a single study of 40 participants with chronic low back pain with a neuropathic component. It found no difference in pain scores between milnacipran 100 mg to 200 mg daily or placebo after six weeks (very low quality evidence). Adverse event rates were similar between treatments, with too few data to draw conclusions (very low quality evidence). There was no evidence to support the use of milnacipran to treat neuropathic pain conditions.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Unknown 164 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 38 23%
Student > Bachelor 19 12%
Student > Ph. D. Student 13 8%
Student > Doctoral Student 12 7%
Researcher 9 5%
Other 29 18%
Unknown 45 27%
Readers by discipline Count As %
Medicine and Dentistry 58 35%
Nursing and Health Professions 22 13%
Neuroscience 6 4%
Psychology 6 4%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 15 9%
Unknown 52 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2021.
All research outputs
#6,325,717
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#7,642
of 11,842 outputs
Outputs of similar age
#67,047
of 276,384 outputs
Outputs of similar age from Cochrane database of systematic reviews
#182
of 285 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,384 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 285 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.